Literature DB >> 10904091

Multiple births and risk of epithelial ovarian cancer.

D C Whiteman1, M F Murphy, L S Cook, D W Cramer, P Hartge, P A Marchbanks, P C Nasca, R B Ness, D M Purdie, H A Risch.   

Abstract

BACKGROUND AND METHODS: Prevailing hypotheses about the causes of ovarian carcinogenesis predict that women with a history of multiple births (twins, triplets, etc.) should be at increased risk of epithelial ovarian cancer. However, the scant available evidence suggests that they may actually be at lower risk. To resolve this issue, we pooled data from eight studies involving 2859 parous women with epithelial ovarian cancer (case patients) and 7434 parous women without ovarian cancer (control women). In addition to assessing their history of multiple births (and the sex of the children, where available), we obtained information on age, parity, oral contraceptive use, and other reproductive factors for each woman. Details of tumor histology were available for all case patients. We estimated the relative risks of various histologic types of ovarian cancers associated with multiple births by using multivariable logistic regression analysis, adjusting for matching and confounding variables.
RESULTS: Among these parous women, 73 case patients (2. 6%) and 257 control women (3.5%) had a history of multiple births. The adjusted summary odds ratio (OR) for developing all types of epithelial ovarian cancer that are associated with multiple births was 0.81 (95% confidence interval [CI] = 0.61-1.08). We found no evidence that risks associated with multiple births differed among women with borderline or invasive tumors and among women with same-sex and opposite-sex offspring from multiple births. The risk reductions appeared specific for nonmucinous tumors (n = 2453; summary adjusted OR = 0.71 [95% CI = 0.52-0.98]); in contrast, associations with mucinous tumors (n = 406) were heterogeneous across studies.
CONCLUSIONS: Parous women with nonmucinous ovarian cancer are no more likely to have a history of multiple births than other parous women, counter to the predictions of current hypotheses for causes of ovarian cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10904091     DOI: 10.1093/jnci/92.14.1172

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

2.  Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort.

Authors:  Inkyung Baik; Mats Lambe; Qin Liu; Lucy Chie; Sven Cnattingius; Lorelei A Mucci; Tomas Riman; Anders Ekbom; Hans-Olov Adami; Chung-Cheng Hsieh
Journal:  Cancer Causes Control       Date:  2008-05-29       Impact factor: 2.506

3.  Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.

Authors:  Helena Schock; Heljä-Marja Surcel; Anne Zeleniuch-Jacquotte; Kjell Grankvist; Hans-Åke Lakso; Renée Turzanski Fortner; Rudolf Kaaks; Eero Pukkala; Matti Lehtinen; Paolo Toniolo; Eva Lundin
Journal:  Endocr Relat Cancer       Date:  2014       Impact factor: 5.678

4.  Relationships of uterine and ovarian tumors to pre-existing chronic conditions.

Authors:  Louise A Brinton; Lori C Sakoda; Kirsten Frederiksen; Mark E Sherman; Susanne K Kjaer; Barry I Graubard; Jorgen H Olsen; Lene Mellemkjaer
Journal:  Gynecol Oncol       Date:  2007-09-07       Impact factor: 5.482

Review 5.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

6.  Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort.

Authors:  Lorelei A Mucci; Paul W Dickman; Mats Lambe; Hans-Olov Adami; Dimitrios Trichopoulos; Tomas Riman; Chung-Cheng Hsieh; Sven Cnattingius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-09       Impact factor: 4.254

7.  Baicalein Is a Phytohormone that Signals Through the Progesterone and Glucocorticoid Receptors.

Authors:  Julia R Austin; Brenna J Kirkpatrick; Rocío Rivera Rodríguez; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2020-03-07       Impact factor: 3.869

8.  Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.

Authors:  Elizabeth M Poole; Melissa A Merritt; Susan J Jordan; Hannah P Yang; Susan E Hankinson; Yikung Park; Bernard Rosner; Penelope M Webb; Daniel W Cramer; Nicolas Wentzensen; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-10       Impact factor: 4.254

9.  MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.

Authors:  Pui-Wah Choi; Wai Wing So; Junzheng Yang; Shubai Liu; Ka Kui Tong; Kin Ming Kwan; Jamie S-L Kwok; Stephen K W Tsui; Shu-Kay Ng; Karen H Hales; Dale B Hales; William R Welch; Christopher P Crum; Wing-Ping Fong; Ross S Berkowitz; Shu-Wing Ng
Journal:  Oncogene       Date:  2020-03-25       Impact factor: 9.867

10.  Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence.

Authors:  Gang Liu; Bhramar Mukherjee; Seunggeun Lee; Alice W Lee; Anna H Wu; Elisa V Bandera; Allan Jensen; Mary Anne Rossing; Kirsten B Moysich; Jenny Chang-Claude; Jennifer A Doherty; Aleksandra Gentry-Maharaj; Lambertus Kiemeney; Simon A Gayther; Francesmary Modugno; Leon Massuger; Ellen L Goode; Brooke L Fridley; Kathryn L Terry; Daniel W Cramer; Susan J Ramus; Hoda Anton-Culver; Argyrios Ziogas; Jonathan P Tyrer; Joellen M Schildkraut; Susanne K Kjaer; Penelope M Webb; Roberta B Ness; Usha Menon; Andrew Berchuck; Paul D Pharoah; Harvey Risch; Celeste Leigh Pearce
Journal:  Am J Epidemiol       Date:  2018-02-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.